{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:04:39Z","timestamp":1789376679817,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02286-x","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:25:58Z","timestamp":1789374358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The anatomical distribution of metabolic tumor burden provides prognostic information beyond whole-body \u00b9\u2078F-FDG PET\/CT metrics in de novo metastatic HER2-positive breast cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6239-0660","authenticated-orcid":false,"given":"Ay\u015feg\u00fcl","family":"Aksu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amine \u0130rem","family":"A\u011fart\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep G\u00fcls\u00fcm","family":"G\u00fc\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir Alper","family":"K\u00fc\u00e7\u00fcker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015feg\u00fcl","family":"\u00d6zdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Turgut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2286_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"2286_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109\u201319.","journal-title":"N Engl J Med"},{"key":"2286_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519\u201330.","journal-title":"Lancet Oncol"},{"key":"2286_CR4","doi-asserted-by":"publisher","first-page":"LBA1008","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1008","volume":"43","author":"SM Tolaney","year":"2025","unstructured":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, et al. Trastuzumab deruxtecan plus pertuzumab versus taxane plus trastuzumab plus pertuzumab for first-line HER2-positive advanced\/metastatic breast cancer: interim results from DESTINY-Breast09. J Clin Oncol. 2025;43:LBA1008.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2286_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa2511218","volume":"394","author":"O Metzger","year":"2026","unstructured":"Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, et al. Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med. 2026;394(5):451\u201362.","journal-title":"N Engl J Med"},{"key":"2286_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597\u2013609.","journal-title":"N Engl J Med"},{"key":"2286_CR7","doi-asserted-by":"publisher","first-page":"TPS1124","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1124","volume":"42","author":"SM Swain","year":"2024","unstructured":"Swain SM, Barrios CH, Basho RK, Curigliano G, Harbeck N, Huang CS, et al. INAVO122: a phase III study of maintenance inavolisib or placebo plus pertuzumab plus trastuzumab in PIK3CA-mutated HER2-positive advanced breast cancer. J Clin Oncol. 2024;42:TPS1124.","journal-title":"J Clin Oncol"},{"key":"2286_CR8","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[\u00b9\u2078F]FDG PET\/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:2706\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2286_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/cam4.119","volume":"2","author":"GA Ulaner","year":"2013","unstructured":"Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, et al. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013;2:725\u201333.","journal-title":"Cancer Med"},{"key":"2286_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-025-02191-7","volume":"28","author":"M Kubeczko","year":"2026","unstructured":"Kubeczko M, d\u2019Amico A, Chrab\u0105ski O, Handkiewicz-Junak D, Polakiewicz-Gilowska A, \u015awiderska K, et al. Prognostic value of baseline FDG PET\/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel. Breast Cancer Res. 2026;28:32.","journal-title":"Breast Cancer Res"},{"key":"2286_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40644-023-00608-0","volume":"23","author":"G Ma","year":"2023","unstructured":"Ma G, You S, Xie Y, Gu B, Liu C, Hu X, et al. Pretreatment \u00b9\u2078F-FDG uptake heterogeneity may predict treatment outcome of combined trastuzumab and pertuzumab therapy in patients with metastatic HER2-positive breast cancer. Cancer Imaging. 2023;23:90.","journal-title":"Cancer Imaging"},{"key":"2286_CR12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2147\/IJGM.S293998","volume":"14","author":"Y Li","year":"2021","unstructured":"Li Y, Liu C, Wang B, Hu X, Gong C, Zhao Y, et al. Prediction of pretreatment \u00b9\u2078F-FDG-PET\/CT parameters on the outcome of first-line therapy in patients with metastatic breast cancer. Int J Gen Med. 2021;14:1797\u2013809.","journal-title":"Int J Gen Med"},{"issue":"12","key":"2286_CR13","doi-asserted-by":"publisher","first-page":"e0225959","DOI":"10.1371\/journal.pone.0225959","volume":"14","author":"W Wen","year":"2019","unstructured":"Wen W, Xuan D, Hu Y, Li X, Liu L, Xu D. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography\/computed tomography in patients with breast cancer: a systematic review and meta-analysis. PLoS ONE. 2019;14(12):e0225959.","journal-title":"PLoS ONE"},{"issue":"2","key":"2286_CR14","first-page":"120","volume":"6","author":"B Marinelli","year":"2016","unstructured":"Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, et al. Prognostic value of FDG PET\/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging. 2016;6(2):120\u20137.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"2286_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2214\/AJR.15.15106","volume":"206","author":"M Taghipour","year":"2016","unstructured":"Taghipour M, Wray R, Sheikhbahaei S, Wright JL, Subramaniam RM. FDG avidity and tumor burden: survival outcomes for patients with recurrent breast cancer. AJR Am J Roentgenol. 2016;206(4):846\u201355.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"2286_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2214\/AJR.14.13906","volume":"205","author":"SH Son","year":"2015","unstructured":"Son SH, Lee SW, Jeong SY, Song BI, Chae YS, Ahn BC, et al. Whole-body metabolic tumor volume, as determined by \u00b9\u2078F-FDG PET\/CT, as a prognostic factor of outcome for patients with breast cancer who have distant metastasis. AJR Am J Roentgenol. 2015;205(4):878\u201385.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"2286_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1091.","journal-title":"BMC Cancer"},{"issue":"14","key":"2286_CR18","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.02222","volume":"41","author":"JK Plichta","year":"2023","unstructured":"Plichta JK, Thomas SM, Hayes DF, Chavez-MacGregor M, Allison K, de los Santos J, et al. Novel prognostic staging system for patients with de novo metastatic breast cancer. J Clin Oncol. 2023;41(14):2546\u201360.","journal-title":"J Clin Oncol"},{"key":"2286_CR19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumor imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2286_CR20","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuz\u00e9 S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786\u20139.","journal-title":"Cancer Res"},{"issue":"6","key":"2286_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2967\/jnumed.113.133801","volume":"55","author":"K Pak","year":"2014","unstructured":"Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55(6):884\u201390.","journal-title":"J Nucl Med"},{"issue":"4","key":"2286_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361\u201387.","journal-title":"Stat Med"},{"issue":"4","key":"2286_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s13139-012-0161-9","volume":"46","author":"J Kim","year":"2012","unstructured":"Kim J, Yoo SW, Kang SR, Cho SG, Oh JR, Chong A, et al. Prognostic significance of metabolic tumor volume measured by \u00b9\u2078F-FDG PET\/CT in operable primary breast cancer. Nucl Med Mol Imaging. 2012;46(4):278\u201385.","journal-title":"Nucl Med Mol Imaging"},{"key":"2286_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13058-025-02087-6","volume":"27","author":"W Whi","year":"2025","unstructured":"Whi W, Shin J, Kim JY, Ahn HK, Park YH, Ahn JS, et al. Prognostic value of FDG PET\/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4\/6 inhibitors. Breast Cancer Res. 2025;27:134.","journal-title":"Breast Cancer Res"},{"key":"2286_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3348\/kjr.2025.1393","volume":"27","author":"M Suh","year":"2026","unstructured":"Suh M, Ryu J, Song H, Jeong JH, Han S, Jeong H, et al. Prognostic significance of pretreatment \u00b9\u2078F-FDG PET\/CT parameters in patients with ER+\/HER2\u2009\u2013\u2009metastatic breast cancer treated with CDK4\/6 inhibitors plus endocrine therapy. Korean J Radiol. 2026;27:363\u201374.","journal-title":"Korean J Radiol"},{"issue":"1","key":"2286_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","volume":"25","author":"YC Fu","year":"2025","unstructured":"Fu YC, Liang SB, Luo M, Wang XP. Intratumoral heterogeneity and drug resistance in cancer. Cancer Cell Int. 2025;25(1):103.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2286_CR27","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/s41598-017-01524-7","volume":"7","author":"S Ha","year":"2017","unstructured":"Ha S, Park S, Bang JI, Kim EK, Lee HY. Metabolic Radiomics for Pretreatment 18F-FDG PET\/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis. Sci Rep. 2017;7(1):1556.","journal-title":"Sci Rep"},{"issue":"8","key":"2286_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/MNM.0000000000001227","volume":"41","author":"K Pak","year":"2020","unstructured":"Pak K, Seok JW, Kim HY, Nguyen TL, Kim K, Kim SJ, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis. Nucl Med Commun. 2020;41(8):824\u20139.","journal-title":"Nucl Med Commun"},{"issue":"10","key":"2286_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s12149-017-1202-3","volume":"31","author":"T Sugihara","year":"2017","unstructured":"Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y, et al. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors. Ann Nucl Med. 2017;31(10):719\u201325.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"2286_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","volume":"9","author":"M Pegram","year":"2023","unstructured":"Pegram M, Jackisch C, Johnston SRD. Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer. NPJ Breast Cancer. 2023;9(1):45.","journal-title":"NPJ Breast Cancer"},{"key":"2286_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1053\/j.semnuclmed.2023.11.005","volume":"54","author":"N Zamani-Siahkali","year":"2024","unstructured":"Zamani-Siahkali N, Mirshahvalad SA, Farbod A, Divband G, Pirich C, Veit-Haibach P, et al. SPECT\/CT, PET\/CT, and PET\/MRI for response assessment of bone metastases. Semin Nucl Med. 2024;54:356\u201370.","journal-title":"Semin Nucl Med"},{"key":"2286_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-018-0047-0","volume":"2","author":"W Chen","year":"2018","unstructured":"Chen W, Hoffmann AD, Liu H, Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol. 2018;2:4.","journal-title":"NPJ Precis Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02286-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02286-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02286-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:25:59Z","timestamp":1789374359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02286-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":32,"alternative-id":["2286"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02286-x","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective study was approved by the institutional review board (Approval Number: 0261, 2026).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the institutional review board, and the requirement for written informed consent was waived.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}